fbpx

Scroll down for references for this edition

PASSWORD:  Diabetes Management Journal is a medical journal exclusively for healthcare professionals. Apply for access here:

DMJ Access Application
Image

Diabetes Management Journal August 2020 References

NEWS & VIEWS REFERENCES

Editor’s Letter

  1. Australian Institute of Aboriginal and Torres Strait Islander Studies. First Encounters and Frontier Conflict https://aiatsis.gov.au/explore/articles/first-encounters-and-frontier-conflict Accessed July 26, 2020
  2. Western Australia Government Heritage Council. Bungarun (Leprosarium), Derby. http://inherit.stateheritage.wa.gov.au/Public/Inventory/Details/8e808e54-1043-45bd-96c2-10000f22197a accessed July 25, 2020.
  3. Wong CK, Yip BH, Mercer S, Griffiths S,Kung K, Wong MC, Chor J, Wong SY. Effect of facemasks on empathy and relational continuity: a randomised controlled trial in primary care. BMC Family Practice. 2013;14:200. DOI: 10.1186/1471-2296-14-200.
  4. Lazzarino AI, Steptoe A, Hamer M, Michie S. Rapid Response: Covid-19: important potential side effects of wearing face masks that we should bear in mind. BMJ 2020;369:m1435
  5. Anfinrud P, Stadnytskyi V, Bax, CE, Bax A. Visualizing Speech-Generated Oral Fluid Droplets with Laser Light Scattering. May 21, 2020 N Engl J Med 2020; 382:2061-2063 DOI: 10.1056/NEJMc2007800
  6. Scopelianos S. Face masks will be mandatory in Melbourne and Mitchell Shires to fight Coronavirus 19 July 2020. https://www.abc.net.au/news/2020-07-19/face-masks-melbourne-victoria-rules-who-needs-to-wear-them/12470640 Accessed July 25, 2020.
  7. PHN Gippsland, Victoria. Aged care workers across Victoria now Required to Wear Masks. July 21, 2020 www.gphn.org.au/news/aged-care-workers-victoria-required-wear-masks/ accessed July 25, 2020.
  8. Australian Medical Association AMA calls on Government for a Stronger Position on Masks to Prevent the Spread of COVID-19. July 23, 2020 https://ama.com.au/gp-network-news/ama-calls-government-stronger-position-masks-prevent-spread-covid-19 Accessed July 25, 2020.
  9. Australian Government Therapeutic Goods Administration. Surgical Masks Query https://tga-search.clients.funnelback.com/s/search.html?query=surgical+masks&collection=tga-artg Accessed July 25, 2020.
  10. Toomey E, Conway Y, Burton C, Smith S, Smalle M, Chan X-H, Adisesh A, Tanveer S, Ross L, Thomson I, Devane D, Greenhalgh T. Extended use or re-use of single-use surgical masks and filtering facepiece respirators: A rapid evidence review.

COVID-19 linked to New Onset DM: https://www.nejm.org/doi/full/10.1056/NEJMc2018688

Living Evidence for Diabetes Public Consultation: https://app.magicapp.org/#/guideline/4045

New Diabetes Australia/RACGP diabetes handbook: https://www.racgp.org.au/diabetes-handbook

Gestational Diabetes: www.diabetesaustralia.com.au/position-statements

FEATURE REFERENCES

p10-14 Diabetic Cheiroarthropathy – A commonly overlooked complication of diabetes

  1. Goyal A, Tiwari V, Gupta Y. Diabetic Hand: A Neglected Complication of Diabetes Mellitus. Cureus. 2018;10(6):e2772.
  2. Hill NE, Roscoe D, Stacey MJ, Chew S. Cheiroarthropathy and tendinopathy in diabetes. Diabet Med. 2019;36(8):939-47.
  3. Nashel J, Steen V. Scleroderma mimics. Curr Rheumatol Rep. 2012;14(1):39-46.
  4. Cherqaoui R, McKenzie S, Nunlee-Bland G. Diabetic cheiroarthropathy: a case report and review of the literature. Case Rep Endocrinol. 2013;2013:257028.
  5. Yoganathan KS, Stevenson A, Martineau, M. Prayer sign due to diabetic cheiroarthropathy. BMJ. 2017;359(j4878 doi: 10.1136/bmj.j4878).
  6. Al-Homood IA. Rheumatic conditions in patients with diabetes mellitus. Clin Rheumatol. 2013;32(5):527-33.
  7. Larkin ME, Barnie A, Braffett BH, Cleary PA, Diminick L, Harth J, Gatcomb P, Golden E, Lipps J, Lorenzi G, Mahony C, Nathan DM, Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Musculoskeletal complications in type 1 diabetes. Diabetes Care. 2014;37(7):1863-9.
  8. Gerrits EG, Landman GW, Nijenhuis-Rosien L, Bilo HJ. Limited joint mobility syndrome in diabetes mellitus: A minireview. World J Diabetes. 2015;6(9):1108-12.
  9. Gokcen N, Cetinkaya Altuntas S, Coskun Benlidayi I, Sert M, Nazlican E, Sarpel T. An overlooked rheumatologic manifestation of diabetes: diabetic cheiroarthropathy. Clin Rheumatol. 2019;38(3):927-32.
  10. Phillips P, Weightman W. Diabetes and the skin. (Part 3--diabetic cheiroarthropathy). Aust Fam Physician. 2005;34(12):1037-8.
  11. Fisher L, Kurtz A, Shipley M. Association between cheiroarthropathy and frozen shoulder in patients with insulin-dependent diabetes mellitus. Br J Rheumatol. 1986;25(2):141-6.
  12. Lister DM, Graham-Brown RA, Burden AC. Resolution of diabetic cheiroarthropathy. Br Med J (Clin Res Ed). 1986;293(6561):1537.
  13. Shah AK, Clatworthy MR, Watson CJ. Diabetic cheiroarthropathy following simultaneous pancreas-kidney transplantation. Transpl Int. 2009;22(6):670-1.
  14. Collier A, Patrick AW, Bell D, Matthews DM, MacIntyre CC, Ewing DJ, et al. Relationship of skin thickness to duration of diabetes, glycemic control, and diabetic complications in male IDDM patients. Diabetes Care. 1989;12(5):309-12.

p16-18 Common Medicines that affect glycaemic stability

  1. Gunton J, Cheung W, Davis T, Colagiuri S, Zoungas S. A new blood glucose management algorithm for type 2 diabetes: a position statement of the Australian Diabetes Society. Melbourne: Australian Diabetes Society; 2016.
  2. Gosmanov AR. A practical and evidence-based approach to management of inpatient diabetes in non-critically ill patients and special clinical populations. Journal of clinical & translational endocrinology. 2016;5:1-6.
  3. Korayem G. Medications affecting glycaemic control. Int Clin Med. 2017;1(1):1-8.
  4. Australian Medicines Handbook online [Internet]. AMH. 2020 [cited 16 May 2020].
  5. Suh S, Park MK. Glucocorticoid-Induced Diabetes Mellitus: An Important but Overlooked Problem. Endocrinol Metab (Seoul). 2017;32(2):180-9.
  6. Wallace MD, Metzger NL. Optimizing the Treatment of Steroid-Induced Hyperglycemia. Annals of Pharmacotherapy. 2018;52(1):86-90.
  7. Diabetes, version 1 [Internet]. eTGs. 2020 [cited 16 May 2020].
  8. Zhang X, Zhao Q. Association of Thiazide-Type Diuretics with Glycemic Changes in Hypertensive Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials. The Journal of Clinical Hypertension. 2016;18(4):342-51.
  9. Scheen AJ. Type 2 Diabetes and Thiazide Diuretics. Current diabetes reports. 2018;18(2):6.
  10. National Heart Foundation of Australia. Guideline for the diagnosis and management of hypertension in adults. Melbourne: National Heart Foundation of Australia; 2016.
  11. Therapeutic Guidelines. Cardiovascular, version 7. Melbourne: Therapeutic Guidelines; 2020.
  12. Rehman A, Setter SM, Vue MH. Drug-Induced Glucose Alterations Part 2: Drug-Induced Hyperglycemia. Diabetes Spectrum. 2011;24(4):234-8.
  13. Fathallah N, Slim R, Larif S, Hmouda H, Ben Salem C. Drug-Induced Hyperglycaemia and Diabetes. Drug Safety. 2015;38(12):1153-68.
  14. Hirst JA, Farmer AJ, Feakins BG, Aronson JK, Stevens RJ. Quantifying the effects of diuretics and beta-adrenoceptor blockers on glycaemic control in diabetes mellitus - a systematic review and meta-analysis. British journal of clinical pharmacology. 2015;79(5):733-43.
  15. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet (London, England). 2007;369(9557):201-7.
  16. Brieger D, Amerena J, Attia J, Bajorek B, Chan KH, Connell C, et al. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation 2018. Heart, Lung and Circulation. 2018;27(10):1209-66.
  17. Atherton JJ, Sindone A, De Pasquale CG, Driscoll A, MacDonald PS, Hopper I, et al. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia 2018. Heart, Lung and Circulation. 2018;27(10):1123-208.
  18. Chen J, Huang X-F, Shao R, Chen C, Deng C. Molecular Mechanisms of Antipsychotic Drug-Induced Diabetes. Front Neurosci. 2017;11:643.
  19. Berhe A, Russom M, Bahran F, Hagos G. Ciprofloxacin and risk of hypolycemia in non-diabetic patients. J Med Case Rep. 2019;13(1):142.
  20. Food and Drug Administration. FDA Drug Safety Communication: safety announcement USA 2018.
  21. Vue MH, Setter SM. Drug-Induced Glucose Alterations Part 1: Drug-Induced Hypoglycemia. Diabetes Spectrum. 2011;24(3):171-7.
  22. Chou HW, Wang JL, Chang CH, Lee JJ, Shau WY, Lai MS. Risk of severe dysglycemia among diabetic patients receiving levofloxacin, ciprofloxacin, or moxifloxacin in Taiwan. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2013;57(7):971-80.
  23. Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, Blumenthal R, Danesh J, Smith GD, DeMets D, Evans S, Law M, MacMahon S, Martin S, Neal B, Poulter N, Preiss D, Ridker P, Roberts I, Rodgers A, Sandercock P, Schulz K, Sever P, Simes J, Smeeth L, Wald N, Yusuf S, Peto R. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet (London, England). 2016;388(10059):2532-61.
  24. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, JUPITER Study Group. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. New England Journal of Medicine. 2008;359(21):2195-207.
  25. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet (London, England). 2010;375(9716):735-42.
  26. Ganda OP. Statin-induced diabetes: incidence, mechanisms, and implications. F1000Res. 2016;5:F1000 Faculty Rev-499.
  27. Choudhury PS, Mukhopadhyay P, Roychowdhary A, Chowdhury S, Ghosh S. Prevalence and Predictors of "New-onset Diabetes after Transplantation" (NODAT) in Renal Transplant Recipients: An Observational Study. Indian J Endocrinol Metab. 2019;23(3):273-7.
  28. Bollmann B-A, Seeliger B, Gottlieb J, Greer M. Risk of post-transplantation diabetes mellitus (PTDM) with different calcineurin inhibitors. European Respiratory Journal. 2016;48(suppl 60):PA4646.
  29. Chakkera HA, Mandarino LJ. Calcineurin inhibition and new-onset diabetes mellitus after transplantation. Transplantation. 2013;95(5):647-52.
  30. Dobrică E-C, Găman M-A, Cozma M-A, Bratu OG, Pantea Stoian A, Diaconu CC. Polypharmacy in Type 2 Diabetes Mellitus: Insights from an Internal Medicine Department. Medicina (Kaunas). 2019;55(8):436.
  31. May M, Schindler C. Clinically and pharmacologically relevant interactions of antidiabetic drugs. Ther Adv Endocrinol Metab. 2016;7(2):69-83.
  32. Shenfield G. Drug interactions with oral hypoglycaemic drugs. Australian Prescriber. 2001;24:83-5.
  33. Triplitt C. Drug Interactions of Medications Commonly Used in Diabetes. Diabetes Spectrum. 2006;19(4):202-11.

p20-22 Pancreatic islet transplantation

  1. Tu E, Twigg SM, Duflou J, Semsarian C. Causes of death in young Australians with type 1 diabetes: a review of coronial postmortem examinations. Med J Aust 2008; 188 (12): 699-702.
  2. Kamel JT, Goodman DJ, Howe K, Cook MJ, Ward GM, Roberts LJ. Assessment of the relationship between hypoglycaemia awareness and autonomic function following islet cell/pancreas transplantation. Diabetes Metab Res Rev. 2015;31(6):646-50.
  3. Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society. Diabetes Care. 2013;36(5):1384-95.
  4. Tattersall RB, Gill GV. Unexplained deaths of type 1 diabetic patients. Diabetic medicine : a journal of the British Diabetic Association. 1991;8(1):49-58.
  5. Rickels MR, Schutta MH, Mueller R, Markmann JF, Barker CF, Naji A, et al. Islet cell hormonal responses to hypoglycemia after human islet transplantation for type 1 diabetes. Diabetes. 2005;54(11):3205-11.
  6. Rickels MR, Peleckis AJ, Markmann E, Dalton-Bakes C, Kong SM, Teff KL, et al. Long-Term Improvement in Glucose Control and Counterregulation by Islet Transplantation for Type 1 Diabetes. J Clin Endocrinol Metab. 2016;101(11):4421-30.
  7. Holmes-Walker DJ, Gunton JE, Hawthorne W, Payk M, Anderson P, Donath S, Loudovaris T, Ward GM, Kay TW, O’Connell PJ. Islet Transplantation Provides Superior Glycemic Control With Less Hypoglycemia Compared With Continuous Subcutaneous Insulin Infusion or Multiple Daily Insulin Injections. Transplantation. 2017 Jun;101(6):1268.
  8. Garg SK, Weinzimer SA, Tamborlane WV, Buckingham BA, Bode BW, Bailey TS, et al. Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes. Diabetes Technol Ther. 2017;19(3):155-63.
  9. Shapiro AM, Pokrywczynska M, Ricordi C. Clinical pancreatic islet transplantation. Nat Rev Endocrinol. 2017;13(5):268-77.
  10. Posselt AM, Szot GL, Frassetto LA, Masharani U, Tavakol M, Amin R, McElroy J, Ramos MD, Kerlan RK, Fong L, Vincenti F, Bluestone JA, Stock PG. Islet Transplantation in Type 1 Diabetic Patients Using Calcineurin Inhibitor-Free Immunosuppressive Protocols Based on T-Cell Adhesion or Costimulation Blockade: Transplantation. 2010 Dec;90(12):1595–601.
  11. Vethakkan SR, Walters JM, Gooley JL, Boston RC, Kay TWH, Goodman DJ, Jenkins AJ, Ward GM. The Incretin Response After Successful Islet Transplantation. Transplantation 01/2014; 97(2):e9-e11.
  12. Bergman RN, Ader M, Huecking K, Van Citters G. Accurate Assessment of -Cell Function: The Hyperbolic Correction. Diabetes. 2002 Feb 1;51(Supplement 1):S212–20.
  13. Vethakkan SR, Jenkins AJ, Kay TWH, Goodman DJ, Walters JM, Gooley JL, Boston RC, Holmes-Walker DJ, Ward GM Improved Second Phase Insulin Secretion and Preserved Insulin Sensitivity After Islet Transplantation. Transplantation 05/2010; 89(10):1291-3.
  14. Vethakkan SR, Walters JM, Gooley JL, Boston RC, Kay TWH, Goodman DJ, Jenkins AJ, Ward GM. Normalized NEFA dynamics during an OGTT after islet transplantation. Transplantation 10/2012; 94(7):e49-e51.
  15. O’Connell PJ, Holmes-Walker DJ, Goodman D, Hawthorne WJ, Loudovaris T, Gunton JE, Thomas HE, Grey ST, Drogemuller CJ, Ward GM, Torpy DJ, Coates PT, Kay TW, the Australian Islet Transplant Consortium. Multicenter Australian Trial of Islet Transplantation: Improving Accessibility and Outcomes: Multicenter Trial of Islet Transplantation. American Journal of Transplantation. 2013 Jul;13(7):1850–8.
  16. Ryan EA, Shandro T, Green K, Paty BW, Senior PA, Bigam D, Shapiro AM, Vantyghem MC. Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes. 2004;53(4):955-62.
  17. Clarke WL, Cox DJ, Gonder-Frederick LA, Julian D, Schlundt D, Polonsky W. Reduced awareness of hypoglycemia in adults with IDDM. A prospective study of hypoglycemic frequency and associated symptoms. Diabetes Care. 1995;18(4):517-22.
  18. Collaborative Islet Transplant Registry. Tenth Annual Report (2015) https://citregistry.org/system/files/10th_AR.pdf
  19. Lee MH, Ward GM, MacIsaac RJ, Howe K, Holmes-Walker DJ, Anderson P, Radford T, Coates PT, Kay TW, OʼConnell PJ, Goodman DJ. Mortality in People with Type 1 Diabetes, Severe Hypoglycemia, and Impaired Awareness of Hypoglycemia Referred for Islet Transplantation: Transplantation Direct. 2018 Nov;4(11):e401.

p24 – p26  Working towards sustained self-management of diabetes

  1. Coleman MT, Newton KS (2005) Supporting Self-management in Patients with Chronic Illness Am Fam Physician. 2005 Oct 15;72(8):1503-1510. https://www.aafp.org/afp/2005/1015/p1503.html
  2. Fisher EG, Boothroyd RI, Coufal MM, et al Peer Support For Self-Management Of Diabetes Improved Outcomes In International Settings (2012) https://doi.org/10.1377/hlthaff.2011.0914
  3. Browne JL, Bennett A, Halliday JA, Holmes-Truscott E, Speight J (2016) Diabetes peer support in Australia: A national survey. Diabetes Victoria, Melbourne
  4. Fisher EB, Boothroyd RI, Elstad EA, Hays L, Henes A, Maslow GR et al, Peer Support of Complex Health Behaviours in Prevention and Disease Management with Special Reference to Diabetes: Systematic Reviews. Clinical Diabetes Endocrinology, 2017; 3:4
  5. Litchman ML, Walker HR, Ng AH, Wawrzynski SE, Oser SM, Greenwood DA., Oser TK (2019). State of the science: a scoping review and gap analysis of diabetes online communities. Journal of diabetes science and technology, 13(3), 466-492.
  6. Embuldeniya G, Veinot P, Bell E, Bell M, Nyhof-Young J, et al (2013) The experience and impact of chronic disease peer support interventions: A qualitative synthesis. https://doi.org/10.1016/j.pec.2013.02.002

p28 – p30 Reality Check – Beyond the gym: exercise options for (almost) every diabetes limitation

  1. Colberg SR, Sigal RJ, Yardley JE, Riddell MC, Dunstan DW, Dempsey PC, Horton ES, Castorino K, Tate DF. Physical activity/exercise and diabetes: a position statement of the American Diabetes Association. Diabetes Care 39, 2065-2079 (2016).
  2. Blair SN, Kohl HW, Paffenbarger RS, Gibbons LW, Macera CA. Physical fitness and all-cause mortality. JAMA 262, 2395-2401 (1989).
  3. Fox KR. The influence of physical activity on mental wellbeing. Public Health Nutrition. 2(3A):411-418 (1999).
  4. Thomas N, Alder E, Leese GP. Barriers to physical activity in patients with diabetes. Postgrad Med J. 80, 287-291 (2004).
  5. Hoare E, Stavreski B, Jennings G, and Kingwell B. Exploring motivation and barriers to physical activity among active and inactive Australian adults. Sports. 5, 47 (2017).
  6. Ball K, Crawford D, and Owen N. Too fat to exercise? Obesity as a barrier to physical activity. Australian and New Zealand Journal of Public Heatlh. 24, 331-333 (2000).
  7. Lascar N, Kennedy A, Hancock B, Jenkins D, Andrews RC, Greenfield S, Narendran P. Attitudes and barriers to exercise in adults with type 1 diabetes (T1DM) and how best to address them: a qualitative study. PLoS One 9(9), e108019 (2014).
  8. Korkiakangas EE, Alahuhta MA, Husman P, Keinänen-Kiukaanniemi S, Taanila AM, Laitinen JH. Motivators and barriers to exercise among adults with a high risk of type 2 diabetes: a qualitative study. Scand J Caring Sci 25(1), 62–9 (2011).
  9. Egan AM, Mahmood WA, Fenton R, Redziniak N, Kyaw Tun T, Sreenan S, McDermott JH. (2013) Barriers to exercise in obese patients with type 2 diabetes. QJM 106(7), 635–8 (2013).
  10. Nelson KM, Reiber G, Boyko EJ. Diet and exercise among adults with type 2 diabetes (findings from NHANES III). Diabetes Care 25, 1722-1728 (2002).
  11. Wilson W, Ary D, Bigard A, Glasgow RE, Toobert DJ, Campbell DR. Psychosocial predictors of self-care behaviours (compliance) and glycemic control in non-insulin-dependent diabetes mellitus. Diabetes Care 9, 614–622 (1986).
  12. Praet SF, van Rooij ES, Wijtvliet A, Boonman-de Winter LJM, Enneking Th, Kuipers H, Stehouwer CDA, van Loon LJC. Brisk walking compared with an individualised medical fitness programme for patients with type 2 diabetes: a randomised controlled trial. Diabetologia 51, 736-746 (2008).
  13. Lachman ME, Lipsitz L, Lubben J, Castaneda-Sceppa C, Jette AM. When adults don’t exercise: behavioural strategies to increase physical activity in sedentary middle-aged and older adults. Innovation in Aging 2(1), 1-12 (2018).
  14. Nielsen PJ, Hafdahl AR, Conn VS, Lemaster JW, Brown SA. Meta-analysis of the effect of exercise interventions on fitness outcomes among adults with type 1 and type 2 diabetes. Diab Res Clin Pract 74, 111-120 (2006).
  15. Ashworth NL, Chad KE, Harrison EL, Reeder BA, Marshall SC. Home versus centre based physical activity programs in older adults. Cochrane Database Syst Rev 1, CD004017 (2005).
  16. Kim CJ, Kand DH. Utility of a web-based intervention for individuals with type 2 diabetes: the impact on physical activity levels and glycaemic control. Comput Inform Nurs 24, 337-345 (2006).
  17. Amati F, Barhassat V, Miganne G, Hausman I, Monnin DG, Constanza MC, Golay A. Enhancing regular physical activity and relapse prevention through 1-day therapeutic patient education workshop: A pilot study. Patient Educ Couns 68, 70-78 (2007).
  18. Sevick MA, Napolitano MA, Papandonatos GD, Gordon AJ, Reiser LM, Marcus BH. Cost-effectiveness of alternative approaches for motivating activity in sedentary adults: results of Project STRIDE. Prev Med 45, 54-61 (2007).
  19. Vileikyte L, Peyrot M, Gonzalez JS, Rubin RR, Garrow AP, Stickings D, Waterman C, Ulbrecht JS, Cavanagh PR, Boulton AJM. Predictors of depressive symptoms in persons with diabetic peripheral neuropathy: a longitudinal study. Diabetologia 52, 1265–1273 (2009).
  20. Carrington AL, Mawdsley SK, Morley M, Kincey J, Boulton AJ. Psychological status of diabetic people with or without lower limb dis-ability. Diabetes Res Clin Pract 32, 19–251 (1996).
  21. Palmer S, Vecchio M, Craig JC, Tonelli M, Johnson DW, Nicolucci A, Pellegrini F, Saglimbene V, Logroscino G, Fishbane S, Strippoli GFM. Prevalence of depression in chronic kidney disease: systematic review and meta-analysis of observational studies. Kidney Int 84, 179–191 (2013).
  22. King DK, Glasgow RE, Toobert DJ, Strycker LA, Estabrooks PA, Osuna D, Faber AJ. Self-efficacy, problem solving and social environment support are associated with diabetes self-management behaviours. Diabetes Care 33, 751-753 (2010).
  23. Schmalz DL. ‘I feel fat’: weight-related stigma, body esteem, and BMI as predictors of perceived competence in physical activity. Obesity Facts 3, 15–21 (2010).
  24. Vartanian LR, Novak S.A. Internalized societal attitudes moderate the impact of weight stigma on avoidance of exercise. Obesity 19, 757–762 (2010).
  25. Martin JE, Dubbert P, Katell AP, Thompson JK, Raczynski JR, Lake M, Smith PO, Webster JS, Sikora T, Cohen RE. Behavioural control of exercise in sedentary adults. Journal of Consulting and Clinical Psychology 52, 795–811(1984).
  26. Wankel LM. Decision-making and social support strategies for increasing exercise involvement. Journal of Cardiac Rehabilitation 4, 124–135 (1984).
  27. Swift CS, Armstrong JE, Beerman KA, Campbell RK, Pond-Smith D. Attitudes and beliefs about exercise among persons with non-insulin-dependent diabetes. The Diabetes Educator 21, 533–540 (1995).
  28. Ferrand C, Perrin C, Nasarre S. Motives for regular physical activity in women and men: a qualitative study in French adults with type 2 diabetes, belonging to a patients’ association. Health and Social Care in the Community 16, 511–520 (2008).
  29. Kirk A, Barnett J, Mutrie N. Physical activity consultation for people with Type 2 diabetes. Evidence and guidelines. Diabetic Medicine 24, 809–816 (2007).
  30. Pena KE, Stopka CB, Barak S, Gertner HR Jr, Carmeli E. Effects of low-intensity exercise on patients with peripheral artery disease. Phys Sportsmed 37, 106–110 (2009).
  31. Balducci S, Lacobellis G, Parisi L, Di Biase N, Calandriello E, Leonetti F, Fallucca F. Exercise training can modify the natural history of diabetic peripheral neuropathy. J Diabetes Complications 20, 216–223 (2006).
  32. Lemaster JW, Mueller MJ, Reiber GE, Mehr DR, Madsen RW, Conn VS. Effect of weight-bearing activity on foot ulcer incidence in people with diabetic peripheral neuropathy: feet first randomized controlled trial. Phys Ther 88:1385–1398 (2008).
  33. Colberg SR, Sigal RJ, Fernhall B, Regensteiner JG, Blissmer BJ, Rubin RR, Chasan-Taber L, Albright AL, Braun B, American College of Sports Medicine; American Diabetes Association. Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement. Diabetes Care 33, e147–e167 (2010).
  34. Herriott MT, Colberg SR, Parson HK, Nunnold T, Vinik AI. Effects of 8 weeks of flexibility and resistance training in older adults with type 2 diabetes. Diabetes Care 27, 2988–2989 (2004).

p32 – p34 Food Stuff – It’s Counterintuitive! Malnutrition in obesity

  1. Kaidar-Person O, Person B, Szomstein S, Rosenthal RJ. Nutritional deficiencies in morbidly obese patients: a new form of malnutrition? Part A: vitamins. Obesity Surgery. 2008; 18(7):870–876
  2. Kaidar-Person O, Person B, Szomstein S, Rosenthal RJ. Nutritional deficiencies in morbidly obese patients: a new form of malnutrition? Part B: minerals. Obesity Surgery. 2008;18(8):1028–1034.
  3. Australian Institute of Health and Welfare 2018. Nutrition across the life stages. Cat. no. PHE 227. Canberra: AIHW. DOI 10.25816/5ebcaca1fa7e2
  4. Via M. The malnutrition of obesity: micronutrient deficiencies that promote diabetes. ISRN Endocrinol. 2012 Mar 15; Article ID 103472:1-8
  5. Shannon C, Gervasoni A, Williams T: The bariatric surgery patient. Nutrition considerations. The Australian Family Physician. 2013 August; 42 (8): 547-552
  6. Carson J.S, Khosrozadeh K, Norbury W.B, Herndon D. Nutritional Needs and Support for the Burned Patient. In. Total Burn Care (Fifth Edition). Elsevier: Amsterdam; 2018. Ch 28. p287-300
  7. Argarwal E, Ferguson M, Banks M, Vivanti A, Batterham M, Bauer J, Capra S, Isenring E. Malnutrition, poor food intake, and adverse healthcare outcomes in non-critically ill obese acute care hospital patients. Clinical Nutrition. 2019; 38(2):759-766
  8. Leandro-Merhi VA, de Aquino JL. Determinants of malnutrition and post-operative complications in hospitalized surgical patients. J Health Popul Nutr. 2014;32(3):400-410.
  9. Fonsecaa D, Salaa P, Muner Ferreira A, Santos JR, Torrinhas RS, Bendavid I, Waltzberg DL. Body weight control and energy expenditure. Clinical Nutrition Experimental, August 2018, Volume 20: 55-59
  10. Donini LM, Pinto A, Giusti AM, Lenzi A, Poggiogalle E. Obesity or BMI Paradox? Beneath the tip of the iceberg. Front Nutr. 2020 May 7: 7:53. doi:10.3389/fnut.2020.00053
  11. Lagacé JC, Brochu M, Dionne IJ. A counterintuitive perspective for the role of fat-free mass in metabolic health. J Cachexia Sarcopenia Muscle. 2020;11(2):343-347.
  12. Pujia A, Gazzaruso C, Ferro Y, Mazza E, Maurotti S, Russo C, Lazzaro V, Romeo S, Montalcini T. Individuals with metabolically healthy overweight/obesity have higher fat utilization than metabolically unhealthy individuals. Nutrients. 2016 Jan 4;8(1):2.
  13. Koves T.R, Ussher J.R, Noland R.C, Slentz D, Mosedale M, Ilkayeva O, Bain J, Stevens R, Dyck JRB, Newgard CB, Lopaschuk GD, Muoio DM. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab. 2008;7:45–56.
  14. Den Besten G, Bleeker A, Gerding A, Karen van Eunen1,2,3, Rick Havinga1, Theo H. van Dijk4, Maaike H. Oosterveer1, Johan W. Jonker1, Albert K. Groen1,2,3,4, Dirk-Jan Reijngoud D-J, Bakker BM. Short-chain fatty acids protect against high-fat diet-induced obesity via a PPARγ-dependent switch from lipogenesis to fat oxidation Diabetes. 2015;64:2398–2408.
  15. Romieu I, Dossus L, Barquera S, Blottière HM, Franks PW, Gunter M, Hwalla N, Hursting SD , Leitzmann M, Margetts B ,Nishida C, Potischman N, Seidell J, Stepien M, Wang Y, Westerterp K, Winichagoon P, Wiseman M, Willett WC, IARC working group on Energy Balance and Obesity. Energy balance and obesity: what are the main drivers? Cancer Causes Control. 2017;28(3):247-258.
  16. Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, Almeida M, Arumugam M, Batto J-M, Kennedy S, Leonard P, Li JH, Burgdorf K, Grarup N, Jørgensen T, Brandslund I, Nielsen HB, Juncker AS, Bertalan M, Levenez F, Pons N, Rasmussen S, Sunagawa S, Tap J, Tims S, Zoetendal EG, Brunak S, Clément K, Doré J, Kleerebezem M, Kristiansen K, Renault P, Sicheritz-Ponten T, de Vos WM, Zucker J-D, Raes J, Hansen T, MetaHIT consortium; Bork P, Wang J, Ehrlich SD, Pedersen O. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013;500(7464):541-546.

-- ENDS --